Approximately one third of all human epithelial cancers express high levels of epithelial growth factor receptors (EGFr).There is good evidence that many tumor cells are ill-equipped to handle deprivation of growth-promoting signals, much more so than normal cells. Monoclonal antibodies (MAbs) that are able to block the binding of EGF to receptors on malignant cells might inhibit cell proliferation; this plausible working hypothesis is the base of studies involving the use of antireceptor antibodies in selective anticancer therapy.
Go to Previous Page
Go to Next Page